Easily Automate PK Assays for Human IgG Drugs in Preclinical Species
News Jul 27, 2017
Image Credit: Andrew Alliance
Lumigen Inc. (A Beckman Coulter Company) presented a poster demonstrating the use of Andrew the pipetting robot with their SPARCL Pharmacokinetic Immunoassay kits at the AAPS NBC event in San Diego. The poster summarizes Andrew’s accuracy and error free execution of the SPARCL kits leading to improved efficiency, reduced PK assay development and cost, all while increasing profitability. The specific poster relates to measuring IgG drug concentration in a pre-clinical setting.
The combination of these two unique technologies allows for a typical ELISA workflow that takes days from the start of the process (starting with coating plates) into just a couple of hours from start to finish.
The data and resulting analysis concludes that the combination of the Andrew robot with the Life Diagnostics SPARCL PK kit may be a way for CRO’s to improve efficiencies, reduce PK assay development time and cost, reduce labor and increase profitability.
SPARCLTM (Spatial Proximity Analyte Reagent Capture Luminescence) technology is a proximity dependent chemiluminescent detection method. In a SPARCL assay, a chemiluminescent compound (acridan) is brought into close proximity to an oxidative enzyme (horseradish peroxidase, HRP) through specific antigen/antibody interaction. A flash of light proportional to the quantity of analyte present in the sample is generated upon addition of a trigger solution containing hydrogen peroxide. A background reducing agent (BGR) is often used to enhance S/N ratios. There is no need to remove excess reactants. There are no washing steps.
The SPARCL PK kit was run according to the directions provided by the manufacturer (Life Diagnostics) by giving the pipetting instructions to the Andrew robot. Briefly, Andrew made the dilutions for the standard curve and QC’s, pipetted the antibodies, calibrators and QC’s into the wells of the 96 well plates. The 96 well plate was incubated at room temperature for 30 minutes on a orbital shaker set at 350 revolutions per minute. After the incubation time was complete, the plate was moved to the LUMIstar Omega luminometer. The LUMIstar was instructed to inject the trigger solution and collect the emitted light.
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Simple Sugar Prevents Neurodegeneration in Lysosomal Storage DiseaseNews
New therapeutic approach may one day delay neurodegeneration typical of a disease called mucopolysaccharidoses IIIB (MPS IIIB)READ MORE
Penn Medicine Biochemist Receives Major Award for Research on Epigenetic Protein Modifications via Mass SpecNews
Benjamin A.Garcia, PhD, an expert in quantitative proteomics and Presidential Professor of Biochemistry and Biophysics in the Perelman School of Medicine at the University of Pennsylvania, has been awarded the Biemann Medal by the American Society for Mass Spectrometry (ASMS). The early-career award recognizes significant achievement in basic or applied mass spectrometry.